Latest News and Press Releases

EMERALD study met both its primary end points of progression-free survival (PFS) in overall population and in ESR1 mutated patientsPFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in...

Q1 2022 TYMLOS® product net revenue of $43 million vs. $45 million in Q1 2021° Q1 results: in-line with previously guided 1H 2022 company target of $97 million° Reiterating FY 2022 TYMLOS Net Revenue...

BOSTON, April 25, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday,...

Focus: RAD011, an investigational synthetic cannabidiol oral solutionWebcast details: 10:00am to 12:00pm for current or prospective investors and sell side analystsObjectives: asset overview, science,...

BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective...

Exclusive extension of research discovery collaboration with Mass General Hospital (MGH)Focus of the program: development of novel oral SIK inhibitors for musculoskeletal diseasesExtension of activity...

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that Kelly Martin, CEO, has accepted an invitation to participate in a...

Focus: RAD011, our investigational synthetic cannabidiol oral solutionBroad market interest in the underlying science, data, and clinical translation of the assetGoal: provide foundational review of...

Filed sNDA with the FDA ahead of schedule on Friday, February 25, 2022Filing based on the positive ATOM study data previously announced on October 18, 2021There is a 10-month FDA review BOSTON, March...

Q4 2021 TYMLOS® net revenue of $65 million vs. $60 million in Q4 2020, up 9%This is a record quarter – over 18 quarters – since the launch in May 2017FY 2021 TYMLOS Net Revenue of $219 vs. $208...